Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
NCT07535905
Summary
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike. Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.
Eligibility
Inclusion Criteria: * At least 18 years of age; * Ability to understand the purposes and risks of the trial and has signed a written informed consent form. Have a diagnosis of prostate cancer; * Patient received ADT for a duration of either 6 or 18-36 months as part of the curative intent treatment. Curative intent prostate cancer patients who completed ADT and have had no further ADT for the length of the last ADT injection depot formulation (e.g., if the last ADT injection depot formulation is for 3 months, the patient must have no ADT for 3 months after last injection) * Have effectively castrated testosterone (\< 1.7 nmol/L \[50 ng/dL\]) within 6 weeks of enrollment; * ECOG Performance status 0-2 Exclusion Criteria: * Harbouring certain CYP2D6 alleles (i.e. CYP2D6\*4) or from the chronic use of a CYP2D6 inhibitor(s); * History of blood clots (venous thromboembolism or pulmonary embolism); * History of stroke or transient ischemic attack (TIA); * Reduced liver function within last 120 days prior to enrolment, defined as follows: 1. Total Bilirubin: 1.5 \> upper limit of normal (ULN) (For Gilbert's syndrome, if total bilirubin is \<1.5 x ULN, measure direct and indirect bilirubin. If direct bilirubin is greater than 1.5 x ULN, participant is ineligible; 2. AST(SGOT) and ALT(SGPT): \> 2.5x ULN; 3. Or other liver disease as deemed ineligible by the investigator * Baseline QT/QTc \> 500ms; * Active therapy with selective serotonin reuptake inhibitor (SSRI) antidepressants (e.g. paroxetine, a known CYP2D6 inhibitor); * Active therapy with coumarin-type anticoagulants; * Active therapy with cytotoxic agents; * Active therapy with aromatase inhibitors; * Other invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin; * Treatment with a non-approved or experimental drug during the 3 months before informed consent; * Patients known to have one of the following hereditary illnesses; galactose- intolerance, Lapp lactase deficiency or glucose-galactose malabsorption; * Any other significant concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this trial;
Conditions3
Interventions1
Related trials
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer — Royal Marsden NHS Foundation Trust
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery — University of Chicago
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) — Fudan University
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) — European Organisation for Research and Treatment of Cancer - EORTC
- Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery — Fudan University
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation — C17 Council
- Tamoxifen Versus Etoposide After First Recurrence in GBM Patients — AHS Cancer Control Alberta
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — AstraZeneca
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07535905